GlaxoSmithKline PLC’s Anoro Ellipta for chronic obstructive pulmonary disease medication goes before the Pulmonary-Allergy Drugs Advisory Committee Sept. 10 with mostly positive results that should give the company high hopes.
GSK is seeking approval of the combination of umeclidinium (UMEC), a long-acting muscarinic antagonist, and vilanterol (VI), a long-acting beta...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?